Therapeutic index of inhaled corticosteroids in asthma: A dose–response comparison on airway hyperresponsiveness and adrenal axis suppression-Reference-Cited by-同舟云学术

Therapeutic index of inhaled corticosteroids in asthma: A dose–response comparison on airway hyperresponsiveness and adrenal axis suppression

Published:2020-06-17 Issue:2 Volume:87 Page:483-493
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Daley‐Yates Peter¹^ORCID,Brealey Noushin¹,Thomas Sebin²,Austin Daren¹,Shabbir Shaila³,Harrison Tim⁴,Singh Dave⁵^ORCID,Barnes Neil⁶⁷

Affiliation:

1. Clinical Pharmacology and Experimental Medicine GlaxoSmithKline plc Uxbridge UK

2. Biostatistics and Programming GlaxoSmithKline plc Bangalore India

3. Medicines Research Centre GlaxoSmithKline plc Stevenage UK

4. Respiratory Research Unit, Nottingham NIHR Biomedical Research Centre University of Nottingham Nottingham UK

5. Medicines Evaluation Unit, University of Manchester Manchester University NHS Foundation Trust Manchester UK

6. Global Medical Franchise GlaxoSmithKline plc Brentford UK

7. William Harvey Research Institute, Barts and The London School of Medicine and Dentistry Queen Mary University of London London UK

Funder

GlaxoSmithKline Japan

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.14406

Reference35 articles.

1. Global Initiative for Asthma (GINA).Global Strategy for Asthma Management and Prevention 2019 update.https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf. Accessed October 25 2019.

2. Inhaled corticosteroids: potency, dose equivalence and therapeutic index

3. ARNUITY ELLIPTA (fluticasone furoate inhalation powder) for oral inhalation use. Highlights of prescribing information. Updated June 2019.https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Arnuity_Ellipta/pdf/ARNUITY%2010ELLIPTA%2010PI%2010PIL%2010IFU.PDF. Accessed November 27 2019.

4. Flixotide 50 125 250 micrograms Evohaler.Fluticasone propionate. Summary of product characteristics. Updated 30 October 2019.https://www.medicines.org.uk/emc/product/3824/smpc. Accessed November 27 2019.

5. Pulmicort Turbohaler 200.Budesonide. Summary of product characteristics. Updated 15 June 2017.https://www.medicines.org.uk/emc/product/1385/smpc. Accessed November 27 2019.

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Efficacy of Budesonide-formoterol in Patients with Acute Attacks of Mild-to-moderate Bronchial Asthma: An Observational Study;Iranian Journal of Allergy, Asthma and Immunology;2024-08-10

2. The underlying factors of occurrence of Mucormycosis in post-COVID-19 patients – A meta-analysis of case histories;Journal of Experimental Biology and Agricultural Sciences;2024-07-15

3. Pharmacokinetic Evaluation of Oral Viscous Budesonide in Paediatric Patients with Eosinophilic Oesophagitis in Repaired Oesophageal Atresia;Pharmaceutics;2024-06-28

4. A Simulation Study of the Effect of Clinical Characteristics and Treatment Choice on Reliever Medication Use, Symptom Control and Exacerbation Risk in Moderate–Severe Asthma;Advances in Therapy;2024-06-25

5. Budesonide Attains Its Wide Clinical Profile by Alternative Kinetics;Pharmaceuticals;2024-04-15